Skip to Main Content
Try STAT+ TODAY
Trending:
STAT+
Biotech
First Opinion
Health
Subscribe Now To access exclusive content, subscribe to STAT+
View Latest View the latest STAT+ stories
Pharmalot
STAT+

FDA scolds two drug makers for TV ads that obscure risk info

  • Ed Silverman

By Ed Silverman Dec. 14, 2016

Reprints
Screen capture via YouTube

File this under “not ready for prime time.”

The US Food and Drug Administration scolded two drug makers for using loud music and fast-paced visuals in their television ads that obscured important risk information.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

About the Author Reprints

Ed Silverman

Ed Silverman

Pharmalot Columnist, Senior Writer

Ed covers the pharmaceutical industry.

Tags

Resistance to FDA’s opioid-disposal plan raises concerns about CADCA,…
Resistance to FDA’s opioid-disposal plan raises concerns about CADCA, a powerful advocacy group
Anti-amyloid drugs and the mystery of treatment-associated brain shrinkage
Anti-amyloid drugs and the mystery of treatment-associated brain shrinkage
The Inflation Reduction Act will help the U.S. achieve…
The Inflation Reduction Act will help the U.S. achieve maximum vaccine access and uptake, but access…
Resistance to FDA’s opioid-disposal plan raises concerns about CADCA,…
Resistance to FDA’s opioid-disposal plan raises concerns about CADCA, a powerful advocacy group
PhRMA, once invincible in Washington, has lost its edge
PhRMA, once invincible in Washington, has lost its edge
‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion…
‘Skinny labels’ on biosimilar medicines saved Medicare $1.5 billion over a recent five-year period

Comments are closed.

Recommended Stories